Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY25 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $5.57 +0.54%
Revenue Growth %: -7.0%
Financial Fact:
Research and development expense: 19.4M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Revenue Growth %: -7.0%
Financial Fact:
Research and development expense: 19.4M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.00, $0.01 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $205.7 million versus the consensus estimate of $204.97 million.
GUIDANCE:
Myriad Genetics sees FY2025 EPS of ($0.02)-$0.02, versus the consensus of $0.01. Myriad Genetics sees FY2025 revenue of $818-828 million, versus the consensus of $822.4 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- CNB Financial (CCNE) Misses Q3 EPS by 6c
- Integra LifeSciences (IART) Tops Q3 EPS by 3c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
